FDA outlines a potential ibogaine trial, while Compass discusses pricing and branding amid psychedelic policy and market developments

The FDA has asked the field for input on a potential early-stage ibogaine clinical trial, proposing sequential dose-ascending groups capped at 10 mg/kg, one-at-a-time dosing, inpatient cardiac monitoring that could last up to 36 hours, CYP2D6 genotyping, medication restrictions, strict stopping rules, and cognitive testing over 12 months. The request forms part of a broader federal effort involving NIDA and ARPA-H to coordinate ibogaine research. The bulletin also covers Compass Pathways' possible pricing, labeling, and gradual launch strategy; potential brand names for LSD and psilocybin products; psychedelic CEOs appearing at a MAHA event; New Mexico's planned medical psilocybin launch and landlord-related opposition; and a 1967 LSD manual's warning against ending sessions early.